Clinical Research on Retinal Neovascularization of Diabetic Retinopathy

Status:

TERMINATED

Clinical Research on Retinal Neovascularization of Diabetic Retinopathy

Lead Sponsor:

Tianjin Medical University

Conditions:

The Mechanism of Retinal Neovascularization of Diabetic

Retinopathy.

Eligibility:

All Genders

45-74 years

Phase:

Brief Summary

Retinal neovascularization of diabetic retinopathy might be associated with genetic risk factors and environmental risk factors.

Eligibility Criteria

Inclusion

T2DM was diagnosed according to the World Health Organization Expert Consultation Report 1999 and consisted of one of the following: fasting blood glucose (FBG) ≥7.0 mmol/L (≥126 mg/dL), blood glucose ≥11.1 mmol/L (≥200 mg/dL) 2 hours after an oral glucose tolerance test (OGTT); or a random blood glucose ≥11.1 mmol/L (≥200 mg/dL).
DR was clinically graded in accordance with the International Clinical Diabetic Retinopathy guidelines based on fundus fluorescence angiography.
All participants with PDR underwent a comprehensive dilated fundus examination to detect DR by indirect ophthalmoscopy and were diagnosed by fundus fluorescence angiography.

Exclusion

Patients were excluded if they had acute complications of diabetes mellitus, type 1 diabetes mellitus, other types of diabetes, serious cardiovascular, hepatic, nephritic or other complications, other serious primary diseases or mental illness.

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01229540

Last Update

October 27 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)